In a report released today, Marcus Curley from UBS maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a price target of A$36.00. The company’s shares closed yesterday at $18.30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Curley is ranked #8922 out of 9371 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Telix Pharmaceuticals Ltd. with a $21.76 average price target, a 18.91% upside from current levels. In a report released yesterday, Bell Potter also maintained a Buy rating on the stock with a A$36.00 price target.
TLPPF market cap is currently $5.44B and has a P/E ratio of 162.15.
Read More on TLPPF:
- Telix Pharmaceuticals to Release Shares from Voluntary Escrow
- Telix Pharmaceuticals: Strong Financial Performance and Promising Growth Prospects Lead to Buy Rating
- Telix Pharmaceuticals Reports Robust Q1 2025 Revenue Growth and Strategic Expansions
- Telix Pharmaceuticals Reports Promising Results for TLX101 Glioma Therapy
- Telix Pharmaceuticals Announces Registry Office Relocation in Sydney